Overview
Truveris provides technology and data analytics for the prescription drug sector, working within the pharmacy supply chain. It serves payers, brokers, and manufacturers with insights and tools to manage pharmacy benefits more effectively. The core offering includes technology solutions and data analytics services for cost containment, clinical guidance, and strategic program design, plus patient access programs that help pharmaceutical brands reach patients and anticipate market shifts. Truveris helps clients stay ahead of regulatory changes (such as FDA recalls) and navigate evolving pharmacy rules. Its goal is to deliver clear, confident insights into pharmacy benefits to improve employee health, productivity, and satisfaction while supporting client growth with branded programs and advisory services.
Work here?Claim your company
Simplify's take
What believers are saying
- Truveris launched its Center of Excellence on March 31, 2026, widening advisory depth.
- CAA 2026 and PBM Kickback Prohibition Act increase demand for independent oversight.
- October 2025 clinical hires and 2026 resources show active product and content expansion.
What critics are saying
- PBMs can bundle pricing and steer clients away, crushing Truveris’ procurement leverage by 2027.
- TrumpRx and PBM reform standardize transparency, commoditizing Truveris’ advisory edge quickly.
- If employers adopt direct purchasing at scale, Truveris loses its core intermediary role.
What makes Truveris unique
- Truveris built an independent, agnostic PBM transparency platform, not a drug manufacturer.
- Its 2026 Center of Excellence combines PharmDs, analytics, and contract procurement expertise.
- Mark Cuban Cost Plus partnership strengthens Truveris’ transparent-pharmacy positioning since 2024.
Help us improve and share your feedback! Did you find this helpful?
Funding
Industry standards